drugset / Trial / NCT04951713
Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase I study to assess the drug-drug interaction of XZP-3287 and Clarithromycin/Rifampicin. The study also evaluates the pharmacokinetic and tolerability of XZP-3287 in healthy subjects.
Timeline
- Start
- 2021-07
- Primary completion
- 2021-09
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 500 mg | Oral |
| Subject | Rifampin | Small molecule | 600 mg | Oral |
| Subject | XZP-3287 | Unknown | 120 mg | Oral |
| Subject | XZP-3287 | Unknown | 360 mg | Oral |
Indications
No indication recorded.